Mural Oncology Q4 net loss $59.5M, cash $270.9M; nemvaleukin trials on track for 1H 2025 readouts

Mural Oncology plc

Net loss of $59.5M for Q4 2023 includes $15.2M non-cash share-based compensation, mostly one-time spin-out charges.
Cash and equivalents $270.9M; cash runway projected into Q4 2025.
Phase 2 ARTISTRY-6 mucosal melanoma cohort (potentially registrational) top-line data expected 1H 2025.
New recommended phase 2 dose for LFIV dosing (30 µg/kg) to be evaluated in ARTISTRY-6 cohort 3.
Company intends to nominate development candidates for engineered IL-18 and IL-12 therapies in 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mural Oncology plc reported the fourth quarter ended December 31, 2023 results: net income Net loss was $59.5 million for the fourth quarter of 2023.. Guidance reaffirmed.

Period: the fourth quarter ended December 31, 2023
Net income: Net loss was $59.5 million for the fourth quarter of 2023.
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Net loss was $59.5 million for the fourth quarter of 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-036150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.